CHAPEL HILL, N.C., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will ring the Closing Bell at the Nasdaq Stock Exchange to recognize the 10th anniversary of the Company’s creation. Cempra founder, president and chief executive officer Prabhavathi Fernandes, Ph.D., will be joined at the Nasdaq by Cempra employees, investors and colleagues.
“We founded Cempra in 2006 to develop therapies to address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community,” said Dr. Fernandes. “The past decade has been filled with firsts – the development of our first two lead antibiotic product candidates; the development of the first antibiotic to be delivered in oral, IV and liquid suspensions in more than 20 years; and the advancement of our candidates through their first clinical evaluations – including two successful global, pivotal Phase 3 studies. And this year, we will be filing our first New Drug Application to the U.S. Food and Drug Administration for solithromycin for the treatment of community-acquired bacterial pneumonia.”
“These milestones and everything in between have been possible because of the talents of our team, the support of our shareholders, and the guidance of our board and advisors. We are very proud of how far we have come, and look forward to continuing to grow our pipeline and advance therapies to make a difference in the lives of our patients and in the community.”
A live webcast of the NASDAQ Closing Bell Ceremony (starting at 3:45 p.m. Eastern Time on Jan. 28) will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.
Photos from the event will be available at: http://www.nasdaq.com/reference/marketsite_events.stm.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
Robert H. Uhl
Westwicke Partners, LLC